Somatostatin analogues improve health-related quality of life in polycystic liver disease: A pooled analysis of two randomised, placebo-controlled trials

M. K. Neijenhuis, T. J G Gevers, F. Nevens, Marie C Hogan, Vicente Torres, W. Kievit, J. P H Drenth

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background Polycystic liver disease is associated with impaired health-related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease. Aim To determine whether somatostatin analogues improve HRQL and to identify factors associated with change in HRQL in polycystic liver disease. Methods We pooled data from two randomized, double-blind, placebo-controlled trials that evaluated HRQL using the Short-Form 36 (SF-36) in 96 polycystic liver disease patients treated 6-12 months with somatostatin analogues or placebo. The SF-36 contains a summarizing physical and mental component score and was administered at baseline and at the end of treatment. We used random effect models to delineate the effect of somatostatin analogues on HRQL. We determined the effect of demographics, height-adjusted liver volume, change in liver volume, somatostatin analogue-associated side effects with change in HRQL. In patients with autosomal dominant polycystic kidney disease, we estimated the effect of height-adjusted kidney volume and change in kidney volume in relation to HRQL. Results Physical component scores improved with somatostatin analogues, but remained unchanged with placebo (3.41 ± 1.29 vs. -0.71 ± 1.54, P = 0.044). Treatment had no impact on the mental component score. Large liver volume was independently associated with larger HRQL decline during follow up (-4.04 ± 2.02 points per logarithm liver volume, P = 0.049). In autosomal dominant polycystic kidney disease, patients with large liver and kidney volumes had larger decline in HRQL (5.36 ± 2.54 points per logarithm liver volume; P = 0.040 and -4.00 ± 1.88 per logarithm kidney volume; P = 0.039). Conclusion Somatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.

Original languageEnglish (US)
Pages (from-to)591-598
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume42
Issue number5
DOIs
StatePublished - Sep 1 2015

Fingerprint

Somatostatin
Randomized Controlled Trials
Placebos
Quality of Life
Liver
Kidney
Autosomal Dominant Polycystic Kidney
Hepatomegaly
Polycystic liver disease
Demography

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Somatostatin analogues improve health-related quality of life in polycystic liver disease : A pooled analysis of two randomised, placebo-controlled trials. / Neijenhuis, M. K.; Gevers, T. J G; Nevens, F.; Hogan, Marie C; Torres, Vicente; Kievit, W.; Drenth, J. P H.

In: Alimentary Pharmacology and Therapeutics, Vol. 42, No. 5, 01.09.2015, p. 591-598.

Research output: Contribution to journalArticle

@article{9184a64cdf1b4f7dab20f7e990b128c9,
title = "Somatostatin analogues improve health-related quality of life in polycystic liver disease: A pooled analysis of two randomised, placebo-controlled trials",
abstract = "Background Polycystic liver disease is associated with impaired health-related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease. Aim To determine whether somatostatin analogues improve HRQL and to identify factors associated with change in HRQL in polycystic liver disease. Methods We pooled data from two randomized, double-blind, placebo-controlled trials that evaluated HRQL using the Short-Form 36 (SF-36) in 96 polycystic liver disease patients treated 6-12 months with somatostatin analogues or placebo. The SF-36 contains a summarizing physical and mental component score and was administered at baseline and at the end of treatment. We used random effect models to delineate the effect of somatostatin analogues on HRQL. We determined the effect of demographics, height-adjusted liver volume, change in liver volume, somatostatin analogue-associated side effects with change in HRQL. In patients with autosomal dominant polycystic kidney disease, we estimated the effect of height-adjusted kidney volume and change in kidney volume in relation to HRQL. Results Physical component scores improved with somatostatin analogues, but remained unchanged with placebo (3.41 ± 1.29 vs. -0.71 ± 1.54, P = 0.044). Treatment had no impact on the mental component score. Large liver volume was independently associated with larger HRQL decline during follow up (-4.04 ± 2.02 points per logarithm liver volume, P = 0.049). In autosomal dominant polycystic kidney disease, patients with large liver and kidney volumes had larger decline in HRQL (5.36 ± 2.54 points per logarithm liver volume; P = 0.040 and -4.00 ± 1.88 per logarithm kidney volume; P = 0.039). Conclusion Somatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.",
author = "Neijenhuis, {M. K.} and Gevers, {T. J G} and F. Nevens and Hogan, {Marie C} and Vicente Torres and W. Kievit and Drenth, {J. P H}",
year = "2015",
month = "9",
day = "1",
doi = "10.1111/apt.13301",
language = "English (US)",
volume = "42",
pages = "591--598",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Somatostatin analogues improve health-related quality of life in polycystic liver disease

T2 - A pooled analysis of two randomised, placebo-controlled trials

AU - Neijenhuis, M. K.

AU - Gevers, T. J G

AU - Nevens, F.

AU - Hogan, Marie C

AU - Torres, Vicente

AU - Kievit, W.

AU - Drenth, J. P H

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Background Polycystic liver disease is associated with impaired health-related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease. Aim To determine whether somatostatin analogues improve HRQL and to identify factors associated with change in HRQL in polycystic liver disease. Methods We pooled data from two randomized, double-blind, placebo-controlled trials that evaluated HRQL using the Short-Form 36 (SF-36) in 96 polycystic liver disease patients treated 6-12 months with somatostatin analogues or placebo. The SF-36 contains a summarizing physical and mental component score and was administered at baseline and at the end of treatment. We used random effect models to delineate the effect of somatostatin analogues on HRQL. We determined the effect of demographics, height-adjusted liver volume, change in liver volume, somatostatin analogue-associated side effects with change in HRQL. In patients with autosomal dominant polycystic kidney disease, we estimated the effect of height-adjusted kidney volume and change in kidney volume in relation to HRQL. Results Physical component scores improved with somatostatin analogues, but remained unchanged with placebo (3.41 ± 1.29 vs. -0.71 ± 1.54, P = 0.044). Treatment had no impact on the mental component score. Large liver volume was independently associated with larger HRQL decline during follow up (-4.04 ± 2.02 points per logarithm liver volume, P = 0.049). In autosomal dominant polycystic kidney disease, patients with large liver and kidney volumes had larger decline in HRQL (5.36 ± 2.54 points per logarithm liver volume; P = 0.040 and -4.00 ± 1.88 per logarithm kidney volume; P = 0.039). Conclusion Somatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.

AB - Background Polycystic liver disease is associated with impaired health-related quality of life (HRQL). Somatostatin analogues reduce hepatomegaly in polycystic liver disease. Aim To determine whether somatostatin analogues improve HRQL and to identify factors associated with change in HRQL in polycystic liver disease. Methods We pooled data from two randomized, double-blind, placebo-controlled trials that evaluated HRQL using the Short-Form 36 (SF-36) in 96 polycystic liver disease patients treated 6-12 months with somatostatin analogues or placebo. The SF-36 contains a summarizing physical and mental component score and was administered at baseline and at the end of treatment. We used random effect models to delineate the effect of somatostatin analogues on HRQL. We determined the effect of demographics, height-adjusted liver volume, change in liver volume, somatostatin analogue-associated side effects with change in HRQL. In patients with autosomal dominant polycystic kidney disease, we estimated the effect of height-adjusted kidney volume and change in kidney volume in relation to HRQL. Results Physical component scores improved with somatostatin analogues, but remained unchanged with placebo (3.41 ± 1.29 vs. -0.71 ± 1.54, P = 0.044). Treatment had no impact on the mental component score. Large liver volume was independently associated with larger HRQL decline during follow up (-4.04 ± 2.02 points per logarithm liver volume, P = 0.049). In autosomal dominant polycystic kidney disease, patients with large liver and kidney volumes had larger decline in HRQL (5.36 ± 2.54 points per logarithm liver volume; P = 0.040 and -4.00 ± 1.88 per logarithm kidney volume; P = 0.039). Conclusion Somatostatin analogues improve HRQL in symptomatic polycystic liver disease. Halting the progressive nature of polycystic liver disease is necessary to prevent further decline of HRQL in severe hepatomegaly.

UR - http://www.scopus.com/inward/record.url?scp=84938548841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938548841&partnerID=8YFLogxK

U2 - 10.1111/apt.13301

DO - 10.1111/apt.13301

M3 - Article

C2 - 26129925

AN - SCOPUS:84938548841

VL - 42

SP - 591

EP - 598

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -